Biodesix Announces New Data on the VeriStrat Test to Be Presented at the 2025 ASCO Annual Meeting
New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)'s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy
来自INSIGHT研究的新数据表明，VeriStrat宿主免疫分类器（HIC）能够预测接受免疫治疗的非小细胞肺癌患者的总体生存率。
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center.
科罗拉多州路易斯维尔，2025年5月22日（环球新闻通讯）——Biodesix公司（纳斯达克：BDSX），一家领先的诊断解决方案公司，今天宣布将在2025年美国临床肿瘤学会（ASCO）年度会议上展示新数据，该会议将于5月31日星期六东部时间下午2:30在伊利诺伊州芝加哥举行。题为“宿主免疫分类器预测PD-L1≥50%转移性NSCLC中化疗免疫疗法生存”的演示将展示来自INSIGHT研究的数据（NCT03289780），该研究招募了超过5000名非小细胞肺癌（NSCLC）患者。该数据将由纽约大学兰戈尼Perlmutter癌症中心的胸部肿瘤学主任Dr. Vamsidhar Velcheti医学博士呈现。
The VeriStrat test measures a patient's immune response to lung cancer and is reported as either Host Immune Classifier Hot (VeriStrat Good) or Host Immune Classifier Cold (VeriStrat Poor). The new data strengthens prior findings and demonstrates statistically significant improvement of overall survival (OS) in patients with a VeriStrat Poor result when receiving immunotherapy combined with chemotherapy versus immunotherapy as a single agent. Notably, the two-year survival rate was more than three times higher in patients receiving immunotherapy plus chemotherapy compared to those who received immunotherapy alone. Additionally, patients with a VeriStrat Good result had comparable survival when receiving either treatment regimen.
VeriStrat测试测量患者对肺癌的免疫反应，并分为宿主免疫分类器热（VeriStrat好）或宿主免疫分类器冷（VeriStrat差）。新数据显示，与单一免疫治疗相比，在接受化疗联合免疫治疗的VeriStrat差结果的患者中，总体生存率（OS）显著提高。值得注意的是，接受免疫治疗加化疗的患者的两年生存率是接受单独免疫治疗患者的三倍以上。此外，VeriStrat好的患者在接受任何治疗方案时生存率相当。
"Immunotherapy treatments represent one of the most important recent innovations in lung cancer treatment, unfortunately some patients do not respond to these treatments while others may experience adverse reactions," said Gary Pestano, Ph.D., Chief Development Officer, Biodesix. "This new data suggests that the VeriStrat test has the potential to help oncologists evaluate the benefits and risks of certain treatments for specific patients. The VeriStrat test may then be an aid in decision-making on whether to escalate or de-escalate treatment and improve patient outcomes."
Biodesix的首席发展官Gary Pestano博士表示：“免疫治疗是肺癌治疗中最近最重要的创新之一，然而，一些患者对这些治疗无反应，另一些则可能会出现不良反应。这个新数据表明VeriStrat测试有可能帮助肿瘤医生评估特定患者某些治疗的收益与风险。然后，VeriStrat测试可能会在是否加大或减少治疗和改善患者结果的决策中提供支持。”
Preliminary results from a different ongoing study suggest that the VeriStrat test may have similar indications in patients with other types of solid tumors. Data from this study is expected to be published later in 2025.
来自另一项正在进行的研究的初步结果表明，VeriStrat测试在其他类型的实体瘤患者中可能具有类似的适应症。这项研究的数据预计将在2025年晚些时候发表。
About Biodesix
关于Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix是一家领先的诊断解决方案公司，致力于改善临床护理和患者的结果。Biodesix诊断测试，作为Nodify肺结节风险评估和IQLung癌症治疗指导进行市场推广，支持临床决策，以加快个性化护理并改善肺部疾病患者的结果。Biodesix开发服务为全球领先的生物制药、生命科学和研究机构提供科学、技术和操作能力，以推动诊断测试、工具和治疗方法的发展。获取更多信息，请访问biodesix.com。
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
商标：Biodesix、Biodesix标志、Nodify肺、和IQLung是Biodesix, Inc.的商标或注册商标。
Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285
联系人：
媒体：
Natalie St. Denis，Biodesix公司董事，负责企业传播
natalie.stdenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR Healthcare
chris.brinzey@icrhealthcare.com
(339) 970-2843
投资者：
克里斯·布林泽，合伙人，ICR医疗
chris.brinzey@icrhealthcare.com
(339) 970-2843
译文内容由第三方软件翻译。
